O E TOTAL TRACER A

03-04-05

IFW

Attorney Docket No. 1438.01

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: HUANG et al.)	
Application No.: 10/680,449)	G A T. ': 1605
Filed: October 6, 2003)	Group Art Unit: 1635 Examiner: T. Vivlemore
For: RNA INTERFERENCE USING A UNIVERSAL TARGET)))	Examiner. 1. viviemore

CERTIFICATE OF EXPRESS MAIL

"Express Mail" mailing label number: EV 60057798 US Date of Deposit: March 3, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stacey L. Stamper

3/3/05

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(b)(3)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Attached is a list of documents on form PTO/SB/08A. Copies of U.S. patents are not being submitted pursuant to Pre-OG Notices http://www.uspto.gov/web/offices/pac/dapp/opla/preognotice/idswouscopies.htm (visited 9/15/2003). Copies of non-patent literature are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 CFR § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicants are in no way making any admission as to prior art status of the listed documents, but are instead submitting the listed documents for the sake of full disclosure under 37 CFR § 1.56.

Appl. No. 10/680,449 IDS dated March 3, 2005

To the best of the undersigned person's knowledge, this Information Disclosure Statement is being submitted in accordance with 37 CFR § 1.97(b)(3), before the mailing of a first Office action on merits.

It is believed that neither an extension of time, nor payment of any fee is required in connection with this communication. However, if an extension of time and corresponding extension fee, or any other fee is required, such an extension of time is hereby petitioned for and the Commissioner is authorized to charge any fees, or credit any overpayment, to Deposit Account No. 50-1627.

Respectfully submitted,

Herbert L. Ley III, Ph.D. Registration No. 53,215

Intellectual Property Department Myriad Genetics, Inc. (Customer No. 26698)
320 Wakara Way
Salt Lake City, UT 84108
Telephone: 801-584-3600

Fax:

801-883-3871

Date: March 3, 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless is contains a valid OMB number.

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known				
Application Number	10/680,449			
Filing Date	October 6, 2003			
First Named Inventor	Liwen Huang			
Art Unit_	1635			
Examiner Name	T. Vivlemore			
Attorney Docket Number	1438.01			

			U.S. PATENT	DOCUMENTS_	
	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevan
	No.1	Number-Kind Code ^{2 (if known)}	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear
		2003/0036197	02-20-2003	Glassman et al.	
		6,544,790	04-08-2003	Sabatini	
		2003/0068821	04-10-2003	Lois-Caballe et al.	
		2003/0139363	07-24-2003	Kay et al.	
		2003/0144232	07-31-2003	Agami et al.	
		2003/0144239	07-31-2003	Agami et al.	
		2003/0143597	07-31-2003	Finney et al.	
		2003/0150017	08-07-2003	Mesa et al.	
		2003/0167490	09-04-2003	Hunter et al.	
		2004/0203145	10-14-2004	Zamore et al.	
		2004/0224405	11-11-2004	Leake et al.	
			 .		

FOREIGN PATENT DOCUMENTS						
Examiner Cite No.1	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T	
						_
						┷
						┼
						+-
						+

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless is contains a valid OMB number.

	Substitute for form 1449A/PTO			C	omplete if Known
l in	IFORMATION DISC	:1 ()	SURF	Application Number	10/680,449
	STATEMENT BY APPLICANT			Filing Date	October 6, 2003
				First Named Inventor	Liwen Huang
				Art Unit	1635
	(use as many sheets as necessary)			Examiner Name	T. Vivlemore
Sheet	2	of	4	Attorney Docket Number	1438.01

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ALDER et al., "Gene Silencing in <i>Caenorhabditis elegans</i> by transitive RNA interference," <i>RNA</i> , 2003, 9:25-32.	
		BARGMANN, "High Throughput Reverse Genetics: RNAi Screen in Caenorhabditis elegans," Genome Biology, January 31, 2001, 2(2):reviews 1005.1-1005.3.	
		BOUTLA et al., "Induction of RNA interference in <i>Caenorhabditis elegans</i> by RNAs derived from plants exhibiting post-transcriptional gene silencing," <i>Nucleic Acids Research</i> , February 4, 2002, 30(7):1688-1694.	
		BROWN et al., "Stable and heritable gene silencing in the malaria vector Anopheles stephensi," Nucleic Acids Research, June 13, 2003, 31(15):e85.	
		CHI et al., "Genomewide view of gene silencing by small interfering RNAs," PNAS, May 27, 2003, 100(11):6343-6346.	
		CHICAS et al., "Characteristics of post-transcriptional gene silencing," <i>EMBO reports</i> , September 28, 2001, 2(11):992-996.	
		CHUANG et al., "Specific and heritable genetic interference by double-stranded RNA in Arabidopsis thaliana," PNAS, April 25, 2000, 97(9):4985-4990.	
		COTTRELL et al., "Silence of the strands: RNA interference in eukaryotic pathogens," TRENDS in Microbiology, January 2003, 11(1):37-43.	
		DILLIN, "The specifics of small interfering RNA specificity," PNAS, May 27, 2003, 100(11):6289-6291.	
		FEINBURG et al., "Transport of dsRNA into Cells by Transmembrane Protein SID-1," Science, September 12, 2003, 301:1545-47.	
		FIRE at al., "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans," Nature, February 19, 1998, 391:806-811.	
		FIRON et al., "Identifying essential genes in fungal pathogens of humans," TRENDS in Microbiology, October 2002, 10(10):456-62.	
		HAMILTON et al., "Two classes of short interfering RNA in RNA silencing," EMBO, July 16, 2002, 21(17):4671-4679.	
		HAMMOND et al., "Post-transcriptional gene silencing by double-stranded RNA," <i>Nature</i> , February 2001; 2:110-117.	
		HANNON, "RNA interference," <i>Nature</i> , July 11, 2002, 418:244-251.	
		HEIDENCREICH et al., "AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells," <i>BLOOD</i> , April 15, 2003, 101(8):3157-3163.	
		HIMBER et al., "Transitivity-dependent and –independent cell-to-cell movement of RNA silencing," <i>EMBO</i> , July 10, 2003, 22(17):4523-4533.	
		JORGENSEN, "RNA traffics information systematically in plants," <i>PNAS</i> , September 3, 2002, 99(18):11561-11563.	
		KAMATH et al., "Effectiveness of specific RNA-mediated interference through ingested double- stranded RNA in Caenorhabditis elegans," Genome Biology, 2000, 2(1):research0002.1-0002.9.	

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless is contains a valid OMB number.

	Substitute for form 1449A/PTO			• •	Complete if Known
IN	INFORMATION DISCLOSURE			Application Number	10/680,449
STATEMENT BY APPLICANT		Filing Date	October 6, 2003		
J	OTATEMENT DI ALL EIGANT		First Named Inventor	Liwen Huang	
				Art Unit	1635
	(use as many sheets as necessary)			Examiner Name	T. Vivlemore
Sheet	3	of	4	Attorney Docket Number	1438.01

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
:		KLAHRE et al., "High molecular weight RNAs and small interfering RNAs induce systemic posttranscriptional gene silencing in plants," <i>PNAS</i> , September 3, 2002, 99(18):11981-11986.	
		LIPARDI et al., "RNAi as Random Degradative PCR: siRNA Primers Convert mRNA into dsRNAs that Are Degraded to Generate New siRNAs," Cell, November 2, 2001, 107:297-307.	
		MALHOTRA et al., "Double-stranded RNA-mediated gene silencing of cysteine proteases (falcipain-1 and -2) of <i>Plasmodium falciparum</i> ," <i>Molecular Microbiology</i> , 2002, 45(5):1245-1254.	
		MANGEOT et al., "A universal transgene silencing method based on RNA interference," Nucleic Acids Research, 2004, 32(12):e102 (6 pages).	
		MARTENS et al., "RNAi in <i>Dictyostelium</i> : The Role of RNA-directed RNA Polymerases and Double-stranded RNase," <i>Molecular Biology of the Cell</i> , February 2002, 13:445-453.	
		NGO et al., "Double-stranded RNA induces mRNA degradation in <i>Trypanosoma brucei</i> ," <i>Proc Natl Acad Sci.</i> , December 1998, 95:14687-14692.	
		NISHIKURA, "A Short Primer on RNAi: RNA-Directed RNA Polymerase Acts as a Key Catalyst," Cell, November 16, 2001, 107:415-418.	
		PANDOLFINI et al., "Expression of self-complementary hairpin RNA under the control of the <i>rolC</i> promoter confers systemic disease resistance to plum pox virus without preventing local infection," <i>BMC Biotechnology</i> , June 25, 2003, 3:1-15.	
		ROIGNANT et al., "Absence of transitive and systemic pathways allows cell-specific and isoform-specific RNAi in <i>Drosophila</i> ," RNA, 2003, 9(3):299-308.	
		SCHULTHEISS et al., "A Small GTP-Binding Host Protein Is Required for Entry of Powdery Mildew Fungus into Epidermal Cells of Barley," <i>Plant Physiology</i> , April 2002, 128(4):1447-1454.	
		SCHWARZ et al., "Evidence that siRNAs Function as Guides, Not Primers, in the <i>Drosophila</i> and Human RNAi Pathways," <i>Molecular Cell</i> , September 2002, 10:537-548.	
		SHUEY et al., "RNAi: gene-silencing in therapeutic intervention," <i>Drug Discovery Today</i> , October 2002, 7(20):1040-1046.	
		SIJEN et al., "On the role of RNA Amplification in dsRNA-Triggered Gene Silencing," Cell, November 16, 2001, 107:465-476.	
		TANG et al., "A biochemical framework for RNA silencing in plants," Genes & Development, November 14, 2002, 17:49-63.	
		TUSCHUL et al., "Targeted mRNA degradation by double-stranded RNA in vitro," Genes & Development, October 28, 1999, 13:3191-3197.	
		VAISTIJ et al., "Spreading of RNA Targeting and DNA Methylation in RNA Silencing Requires Transcription of the Target Gene and a Putative RNA-Dependent RNA Polymerase," The Plant Cell, April 2002, 14:857-867.	
		VALDES et al., "Using Double-stranded RNA to Prevent in Vitro and in Vivo Viral Infections by Recombinant Baculovirus," Journal of Biological Chemistry, May 23, 2003, 278(21):19317-19324.	
		VAN HOUDT et al., "RNA Target Sequences Promote Spreading of RNA Silencing," <i>Plant Physiology</i> , January 2003, 131:245-253.	
		VANITHARANI et al., "Short interfering RNA-mediated interference of gene expression and viral DNA accumulation in cultured plant cells," PNAS, August 5, 2003, 100(16):9632-9636.	
		VAUCHERET et al., "Post-transcriptional gene silencing in plants," <i>Journal of Cell Science</i> , 2001, 114:3083-3091.	

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	0.0., 0.0., 0.0., 0.0., 0, 0, 0	
Under the Paperwork Reduction Act of 1995, no	o persons are required to respond to a collection of information unless is contains a valid	OMB number.

Substitute for form 1449A/PTO		Complete if Known			
l IN	IEODMATION DIS	SCI O	SIIDE	Application Number	10/680,449
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	October 6, 2003
				First Named Inventor	Liwen Huang
				Art Unit	1635
	(use as many sheets as necessary)			Examiner Name	T. Vivlemore
Sheet	4	of	4	Attorney Docket Number	1438.01

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		WAGNER et al., "Double-stranded RNA poses puzzle," Nature, February 19, 1998, 391:744-745.	
		WATERHOUSE et al., "Exploring Plant Genomes by RNA-Induced Gene Silencing," <i>Nature Reviews Genetics</i> , January 2003; 4:29-37.	
		WESLEY et al., "Construct design for efficient, effective and high-throughput gene silencing in plants," <i>The Plant Journal</i> , 2001; 27(6):581-590.	
		WILKINSON et al., "RNA Interference Identifies Two Hydroperoxide Metabolizing Enzymes That Are Essential to the Bloodstream Form of the African Trypanosome," <i>The Journal of Biological Chemistry</i> , August 22, 2003; 278(34):31640-31646.	
		WINSTON et al., "Systemic RNAi in C. <i>elegans</i> Requires the Putative Transmembrane Protein SID-1," Science, March 29, 2002, 295:2456-2459.	
Examiner		Date	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.